Craig Antony Dunbar

USPTO Granted Patents = 9 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 97(Granted Patents)

Company Filing History:

4 out of 8

Tarveda Therapeutics, Inc.

patents

2 out of 1,149

Vertex Pharmaceuticals, Inc.

patents

2 out of 11

Placon Therapeutics, Inc.

Years Active: 2015-2022

Loading Chart...

9 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11458206 - Targeted conjugates and particles and formulations thereof (2022-10-04),

2. 10624967 - Targeted conjugates and particles and formulations thereof (2020-04-21),

3. 10322191 - Targeted conjugates and particles and formulations thereof (2019-06-18),

4. 10111853 - Compounds, compositions, and methods for the treatment of cancers (2018-10-30),

5. 10058546 - Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof (2018-08-28),

6. 9750818 - Targeted conjugates and particles and formulations thereof (2017-09-05),

7. 9556214 - Compounds, compositions, and methods for the treatment of cancers (2017-01-31),

8. 9480657 - Cabazitaxel-platinum nanoparticles and methods of using same (2016-11-01),

9. 9012496 - Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof (2015-04-21),

Title: Craig Antony Dunbar: Innovator in Targeted Therapeutics

Introduction

Craig Antony Dunbar is a notable inventor based in Needham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of targeted drug delivery systems. With a total of 9 patents to his name, Dunbar's work focuses on improving the efficacy of therapeutic agents through innovative formulations.

Latest Patents

Dunbar's latest patents include advancements in targeted conjugates and particles, specifically nanoparticles and microparticles. These formulations contain conjugates of active agents, such as therapeutic, prophylactic, or diagnostic agents, attached to targeting moieties via linkers. The design of these nanoparticles and microparticles aims to enhance the temporospatial delivery of active agents and improve biodistribution. Additionally, methods for making these conjugates and administering the formulations to subjects in need, particularly for treating or preventing cancer and infectious diseases, are also provided.

Career Highlights

Throughout his career, Dunbar has worked with prominent companies in the pharmaceutical industry, including Tarveda Therapeutics, Inc. and Vertex Pharmaceuticals, Inc. His experience in these organizations has allowed him to collaborate on groundbreaking projects that push the boundaries of medical science.

Collaborations

Dunbar has collaborated with several professionals in his field, including Rossitza Gueorguieva Alargova and Mark T Bilodeau. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Craig Antony Dunbar is a distinguished inventor whose work in targeted therapeutics has the potential to revolutionize treatment options for various diseases. His innovative approach to drug delivery systems continues to pave the way for future advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.